
Article • In the brain
Gadolinium deposition: A real threat or a phantom debate?
The European Medicines Agency (EMA) decided to suspend authorisation for certain linear gadolinium agents. The review by the Committee for Medicinal Products for Human Use (CHMP) states: “There is currently no evidence that gadolinium deposition in the brain has caused any harm to patients; however EMA has recommended restrictions and suspensions for some intravenous linear agents in order to…